Siplizumab

Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells[1].

Product Specifications

CAS Number

[288392-69-8]

Product Name Alternative

MEDI-507

UNSPSC

12352203

Target

CD2

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/siplizumab.html

Purity

99.83

Solubility

10 mM in DMSO

Smiles

[Siplizumab]

Molecular Weight

(146.25 kDa)

References & Citations

[1]Binder C, et, al. Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin In Vitro. Front Immunol. 2020 Nov 11;11:592553.